Compare BridgeBio Pharma Inc (BBIO) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Recursion Pharmaceuticals Inc — how do they compare? BridgeBio Pharma Inc trades at $84.58 (market cap $16.36B), while Recursion Pharmaceuticals Inc trades at $3.3 (market cap $1.81B). The key difference: BridgeBio Pharma Inc is far larger — about 9× Recursion Pharmaceuticals Inc's market cap, and BridgeBio Pharma Inc is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| BBIO | RXRX | |
|---|---|---|
Market Cap | $16.36B | $1.81B |
Sector | Health | Health |
52-Week High | $90.17 | $6.79 |
52-Week Low | $47.29 | $2.84 |
Enterprise Value | $18.14B | $1.33B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.57, down slightly by 0.12% on the day, with a bullish technical signal from moving averages but mixed oscillators. The company reported Q2 2026 revenue growth driven by Attruby sales, though it missed EPS estimates. With a high P/S ratio of 22.77 and negative profitability metrics, the stock is priced for future growth, supported by strong analyst buy ratings and a $104.56 consensus price target.
The outlook hinges on successful product launches and regulatory approvals, with three potential launches expected within 12 months offering significant upside. Key risks include persistent cash burn, high debt, and execution challenges in bringing new treatments to market, which could pressure the stock if milestones are missed.
RXRX trades at $3.33, up 1.22% in the last session, with a bearish technical signal and RSI near overbought levels. The company reported a Q2 2026 earnings miss with revenue of $54M and a net loss of $519M, reflecting a net margin of -961.97%. Recent news highlights participation in investor conferences and a Genentech partnership advancement, but competitive pressures and slow revenue growth remain concerns.
Outlook is cautious due to persistent losses and high cash burn, though partnerships provide some validation. Risks include execution challenges in drug discovery and reliance on milestone payments. Analysts show a mixed stance with 40% buy ratings, but the stock faces headwinds from weak profitability and bearish technical trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
